Great Point Partners has recapitalized SteriPack, an Irish contract manufacturing and services company serving the medical device and pharmaceutical industries. No financial terms were disclosed.
GREENWICH, CT and MULLINGAR, IRELAND— Great Point Partners (“GPP”), a Greenwich-based private investment firm focused on the health care industry, today announced the growth recapitalization of SteriPack (“SteriPack” or the “Company”). The Company is a leading contract manufacturing and value-added services company serving the medical device and pharmaceutical industries.
SteriPack has been a continuous innovator in the markets that it serves and has grown both its breadth of services as well as geographic presence. From its original base of operations in Ireland, the Company extended its geographic footprint by adding facilities in Poland (2006), Malaysia (2009) and the United States (2012). SteriPack acts as a “one-stop-shop” solution for their customers by providing a full breadth of services from engineering through production and distribution.
“Since Garry Moore founded the business in 1994, SteriPack has been a constant innovator in the medical device contract manufacturing industry and the Company has continuously evolved to meet their clients’ needs through superior customer service and an uncompromising commitment to quality,” said Adam Dolder, Managing Director at GPP.
SteriPack has over 650 employees worldwide and is constantly looking to expand its capabilities and reach, through both organic growth and add-on acquisitions.
“Garry Moore (CEO), Aidan O’Brien (CFO), and the entire SteriPack team have done a phenomenal job leading the Company through two decades of growth. We look forward to helping them expand their global presence and accelerating that growth with an aggressive add-on acquisition strategy as we have done in many of our other successful investments,” added Bret Tenenhaus, Vice President at GPP.
“Great Point’s impressive track record of investing in the health care manufacturing industry and their experience with bolt-on acquisitions made them an ideal partner to help accelerate SteriPack’s growth,” said Garry Moore, founder and CEO of SteriPack. “We have built a great relationship with Great Point since 2015 and are excited to have them as partners, as we strive to better serve our customers around the world.”
As part of Great Point’s investment Robert Thomas of Great Point’s CEO Advisory Board will join SteriPack’s Board of Directors. Mr. Thomas is the former CEO of FoxHollow Technologies, which ultimately achieved a market capitalization of more than $1 billion prior to its sale to EV3.
About Great Point Partners
Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.6 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has committed capital of $286 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III, $286 million in committed capital) and public equity funds (BMVF, approximately $1.1 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on (i) biopharmaceutical/medical device infrastructure, services and supplies, (ii) alternate site care, and (iii) healthcare technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.
SteriPack is a leading contract manufacturing and value-added service provider to the medical device and pharmaceutical (primarily drug-device combination products) industries. Serving some of the largest names in the medical device industry, the Company has experienced impressive customer retention and provides the highest quality and customer service. Headquartered in Ireland with 650 employees, SteriPack operates facilities in Poland, Malaysia, and the United States, a critical and differentiating element for its global client base. SteriPack’s international footprint, high quality products, and integrated services created a strong brand presence in the contract manufacturing market, allowing the company to develop long-standing relationships with blue chip device companies. For more information, please visit https://steripackgroup.com/